Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.

Oral delivery is the most common method for drug administration. However, poor solubility, stability, and bioavailability of many drugs make achieving therapeutic levels via the gastrointestinal (GI) tract challenging. Drug delivery must overcome numerous hurdles, including the acidic gastric environment and the continuous secretion of mucus that protects the GI tract. Nanoparticle drug carriers that can shield drugs from degradation and deliver them to intended sites within the GI tract may enable more efficient and sustained drug delivery. However, the rapid secretion and shedding of GI tract mucus can significantly limit the effectiveness of nanoparticle drug delivery systems. Many types of nanoparticles are efficiently trapped in and rapidly removed by mucus, making controlled release in the GI tract difficult. This review addresses the protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier.

[1]  A. Basit,et al.  Interplay Between Intestinal pH, Transit Time and Feed Status on the In Vivo Performance of pH Responsive Ileo-Colonic Release Systems , 2008, Pharmaceutical Research.

[2]  M. Skurnik,et al.  Interactions between Yersinia enterocolitica and rabbit ileal mucus: growth, adhesion, penetration, and subsequent changes in surface hydrophobicity and ability to adhere to ileal brush border membrane vesicles , 1991, Infection and immunity.

[3]  W. Lehmann,et al.  Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray‐tandem mass spectrometry , 2004, Scandinavian journal of gastroenterology.

[4]  Jeffrey R. Wang,et al.  Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. , 2010, International journal of oncology.

[5]  D. Lewis,et al.  The Transfer of Polystyrene Microspheres from the Gastrointestinal Tract to the Circulation after Oral Administration in the Rat , 1995, The Journal of pharmacy and pharmacology.

[6]  Soriano,et al.  The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. , 2000, Colloids and surfaces. B, Biointerfaces.

[7]  Jung Soo Suk,et al.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. , 2008, Angewandte Chemie.

[8]  L. Montagne,et al.  Effect of diet on mucin kinetics and composition: nutrition and health implications. , 2004, Nutrition reviews.

[9]  P. Artursson,et al.  The Influence of Intestinal Mucus Components on the Diffusion of Drugs , 2004, Pharmaceutical Research.

[10]  J. Hastewell,et al.  Cell biology and active transport processes in the colon , 1991 .

[11]  Michael P Boyle,et al.  The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. , 2009, Biomaterials.

[12]  R. Juanes,et al.  Fluid mixing from viscous fingering. , 2010, Physical review letters.

[13]  M. Qiao,et al.  Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Simon C Watkins,et al.  Role of intestinal mucus in transepithelial passage of bacteria across the intact ileum in vitro. , 1994, Surgery.

[15]  P. Artursson,et al.  Diffusion of drugs in native and purified gastrointestinal mucus. , 1997, Journal of pharmaceutical sciences.

[16]  J. Kreuter,et al.  Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles , 1989 .

[17]  Frederic Lagarce,et al.  Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. , 2010, Nanomedicine.

[18]  J. S. Suk,et al.  Common Gene Therapy Viral Vectors Do Not Efficiently Penetrate Sputum from Cystic Fibrosis Patients , 2011, PloS one.

[19]  T. Kararli Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[20]  D. Graham,et al.  Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins , 1998, Virchows Archiv.

[21]  J. Irache,et al.  Preparation and characterization of lectin-latex conjugates for specific bioadhesion. , 1994, Biomaterials.

[22]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[23]  G. Russell-Jones,et al.  Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. , 1999, International journal of pharmaceutics.

[24]  W. Lehmann,et al.  Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis , 2009, Inflammatory bowel diseases.

[25]  Omid C Farokhzad,et al.  pH-Responsive nanoparticles for drug delivery. , 2010, Molecular pharmaceutics.

[26]  W. Stremmel,et al.  Lipid Based Therapy for Ulcerative Colitis—Modulation of Intestinal Mucus Membrane Phospholipids as a Tool to Influence Inflammation , 2010, International journal of molecular sciences.

[27]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[28]  R. Poulsom,et al.  Alterations in the Composition of the Supramucosal Defense Barrier in Relation to Disease Severity of Ulcerative Colitis , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  F. Autschbach,et al.  Delayed Release Phosphatidylcholine in Chronic-active Ulcerative Colitis: A Randomized, Double-blinded, Dose Finding Study , 2009, Journal of clinical gastroenterology.

[30]  R. Carrier,et al.  Barrier properties of gastrointestinal mucus to nanoparticle transport. , 2010, Macromolecular bioscience.

[31]  Alexander T. Florence,et al.  Enhanced Oral Uptake of Tomato Lectin-Conjugated Nanoparticles in the Rat , 1997, Pharmaceutical Research.

[32]  G. Halbert,et al.  The in Vitro Cell Association of Invasin Coated Polylactide-Co-glycolide Nanoparticles , 2000, Pharmaceutical Research.

[33]  T. Delair,et al.  Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. , 2010, Biomaterials.

[34]  L. Holm,et al.  The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[35]  Jianqing Gao,et al.  Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs , 2010, Expert opinion on drug delivery.

[36]  Claus-Michael Lehr,et al.  Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa , 2001, Pharmaceutical Research.

[37]  H. Blom,et al.  Gastric mucus gel layer thickness measured by direct light microscopy. An experimental study in the rat. , 1988, Scandinavian journal of gastroenterology.

[38]  M. Burger,et al.  Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. , 1974, The Journal of biological chemistry.

[39]  A. Macadam The effect of gastro-intestinal mucus on drug absorption , 1993 .

[40]  S. Michalek,et al.  Effectiveness of Liposomes Possessing Surface-Linked Recombinant B Subunit of Cholera Toxin as an Oral Antigen Delivery System , 1998, Infection and Immunity.

[41]  L. Szentkuti,et al.  Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon , 1997 .

[42]  Mansoor M Amiji,et al.  Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[43]  J. Hardcastle,et al.  Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.

[44]  A. Slomiany,et al.  Lipids associated with rat small-intestinal mucus glycoprotein. , 1983, Carbohydrate research.

[45]  M. Burger Wheat Germ Agglutinin , 2002 .

[46]  Alexander T. Florence,et al.  Utilizing Bacterial Mechanisms of Epithelial Cell Entry: Invasin-induced Oral Uptake of Latex Nanoparticles , 2004, Pharmaceutical Research.

[47]  M. Qiao,et al.  Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[48]  R. Cone,et al.  Barrier properties of mucus. , 2009, Advanced drug delivery reviews.

[49]  Philip Sutton,et al.  Mucin dynamics and enteric pathogens , 2011, Nature Reviews Microbiology.

[50]  Clive G. Wilson,et al.  Drug delivery to the gastrointestinal tract , 1989 .

[51]  G W Halbert,et al.  The Uptake and Translocation of Latex Nanospheres and Microspheres after Oral Administration to Rats , 1989, The Journal of pharmacy and pharmacology.

[52]  L. Lichtenberger The hydrophobic barrier properties of gastrointestinal mucus. , 1995, Annual review of physiology.

[53]  Yen-Chun Peng,et al.  Chemiluminescence assay of mucosal reactive oxygen species in gastric cancer, ulcer and antral mucosa. , 2008, Hepato-gastroenterology.

[54]  P Couvreur,et al.  Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. , 1997, Journal of pharmaceutical sciences.

[55]  K. Ribbeck,et al.  Characterization of particle translocation through mucin hydrogels. , 2010, Biophysical journal.

[56]  R. Newcombe,et al.  Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. , 1994, Gut.

[57]  J. Kountouras,et al.  Reactive oxygen metabolites and upper gastrointestinal diseases. , 2001, Hepato-gastroenterology.

[58]  K. Wan,et al.  Glycoprotein mucin molecular brush on cancer cell surface acting as mechanical barrier against drug delivery , 2010 .

[59]  Yves-Jacques Schneider,et al.  Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[60]  V. Préat,et al.  Fate of polymeric nanocarriers for oral drug delivery , 2011 .

[61]  S. Kerss,et al.  A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents. , 1982, Clinical science.

[62]  T. Hope,et al.  Human Immunodeficiency Virus Type 1 Is Trapped by Acidic but Not by Neutralized Human Cervicovaginal Mucus , 2009, Journal of Virology.

[63]  J. Irache,et al.  Salmonella-like bioadhesive nanoparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .

[65]  Rama Bansil,et al.  Mucin structure, aggregation, physiological functions and biomedical applications , 2006 .

[66]  M D Donovan,et al.  Drug transfer through mucus. , 2001, Advanced drug delivery reviews.

[67]  S. Feng New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers , 2014 .

[68]  C. Probert,et al.  Mucins and inflammatory bowel disease , 2000, Postgraduate medical journal.

[69]  H. Fessi,et al.  Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. , 2005, Critical reviews in therapeutic drug carrier systems.

[70]  Y. Iiboshi,et al.  Role of intestinal mucus on the uptake of latex beads by Peyer's patches and on their transport to mesenteric lymph nodes in rats. , 1999, JPEN. Journal of parenteral and enteral nutrition.

[71]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[72]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[73]  Christopher J H Porter,et al.  Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. , 2008, Advanced drug delivery reviews.

[74]  T. Desai,et al.  Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres , 1997 .

[75]  P. Sinko,et al.  The effect of physical barriers and properties on the oral absorption of particulates. , 1998, Advanced drug delivery reviews.

[76]  M. Schenk,et al.  The mucosal immune system at the gastrointestinal barrier. , 2008, Best practice & research. Clinical gastroenterology.

[77]  Bradley S. Turner,et al.  Viscous fingering of HCI through gastric mucin , 1992, Nature.

[78]  Michael Wirth,et al.  The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. , 2004, Advanced drug delivery reviews.

[79]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[80]  K. M. Lin,et al.  Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[81]  J. S. Suk,et al.  Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. , 2011, Nanomedicine.

[82]  Samuel K. Lai,et al.  Altering Mucus Rheology to “Solidify” Human Mucus at the Nanoscale , 2009, PloS one.

[83]  A. Slomiany,et al.  Hydrogen ion diffusion in dog gastric mucus glycoprotein: effect of associated lipids and covalently bound fatty acids. , 1984, Biochemical and biophysical research communications.

[84]  A. Basit,et al.  An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[85]  C. Probert,et al.  Mucins in the gastrointestinal tract in health and disease. , 2001, Frontiers in bioscience : a journal and virtual library.

[86]  M. Amiji,et al.  Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease , 2008, Gene Therapy.

[87]  N Hussain,et al.  Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. , 2001, Advanced drug delivery reviews.

[88]  Sanjay K. Jain,et al.  In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[89]  J. Robinson,et al.  Some biological issues in oral, controlled drug delivery , 1987 .

[90]  Giovanni Filippo Palmieri,et al.  Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. , 2007, Biomaterials.

[91]  P. Lowe,et al.  Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats , 1994, The Journal of pharmacy and pharmacology.

[92]  Maria José Alonso,et al.  Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport , 2002, Pharmaceutical Research.

[93]  K. Okazaki,et al.  Gastric mucin hydrophobicity: effects of associated and covalently bound lipids, proteolysis, and reduction. , 1988, Biochemistry international.

[94]  A. I. Yudin,et al.  Diffusion of macromolecules and virus-like particles in human cervical mucus. , 2001, Biophysical journal.

[95]  J. Pearson,et al.  The gastroduodenal mucus barrier and its role in protection against luminal pepsins: The effect of 16,16 dimethyl prostaglandin E2, carbopol‐polyacrylate, sucralfate and bismuth subsalicylate , 1994, Journal of gastroenterology and hepatology.

[96]  Mansoor M Amiji,et al.  Polymeric nano- and microparticle technologies for oral gene delivery , 2007, Expert opinion on drug delivery.

[97]  C. Fiocchi Handbook of mucosal immunology , 1994 .

[98]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[99]  D. Owen,et al.  Histochemical alterations of mucin in normal colon, inflammatory bowel disease and colonic adenocarcinoma , 2004, The Histochemical Journal.

[100]  A. Slomiany,et al.  Effect of lipids and proteins on the viscosity of gastric mucus glycoprotein. , 1984, Biochemical and biophysical research communications.

[101]  H Lennernäs,et al.  Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[102]  C. Lehr,et al.  Lectin-mediated drug targeting: history and applications. , 2004, Advanced drug delivery reviews.

[103]  A. Vila,et al.  Design of biodegradable particles for protein delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[104]  Claus-Michael Lehr,et al.  Bioadhesion by Means of Specific Binding of Tomato Lectin , 1992, Pharmaceutical Research.

[105]  D. Bhalla,et al.  Cytochemical analysis of alkaline phosphatase and esterase activities and of lectin-binding and anionic sites in rat and mouse Peyer's patch M cells. , 1983, The American journal of anatomy.

[106]  B. Hirst,et al.  Lectin-mediated mucosal delivery of drugs and microparticles. , 2000, Advanced drug delivery reviews.

[107]  Justin Hanes,et al.  Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. , 2011, Angewandte Chemie.

[108]  S. Ganta,et al.  A review of stimuli-responsive nanocarriers for drug and gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[109]  Y. Kawashima,et al.  Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. , 2001, The Journal of pharmacology and experimental therapeutics.

[110]  P. Artursson,et al.  Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[111]  J. Sheehan,et al.  Structure and macromolecular properties of mucus glycoproteins. , 1988, Monographs in allergy.

[112]  J Woodley,et al.  Bioadhesion: new possibilities for drug administration? , 2001, Clinical pharmacokinetics.

[113]  Hirofumi Takeuchi,et al.  Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. , 2005, Advanced drug delivery reviews.

[114]  H. Florey The secretion and function of intestinal mucus. , 1962, Gastroenterology.

[115]  Samuel K. Lai,et al.  Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses , 2009, Proceedings of the National Academy of Sciences.

[116]  R Weltzin,et al.  Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting , 1996, The Journal of experimental medicine.

[117]  T. Yen,et al.  Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. , 2010, Biomaterials.

[118]  D. A. McCormick,et al.  Mucin depletion in inflammatory bowel disease. , 1990, Journal of clinical pathology.

[119]  Benjamin C. Tang,et al.  Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier , 2009, Proceedings of the National Academy of Sciences.

[120]  Hirofumi Takeuchi,et al.  Mucoadhesive DL-Lactide/Glycolide Copolymer Nanospheres Coated with Chitosan to Improve Oral Delivery of Elcatonin , 2000, Pharmaceutical development and technology.

[121]  Ick Chan Kwon,et al.  Targeted delivery of low molecular drugs using chitosan and its derivatives. , 2010, Advanced drug delivery reviews.

[122]  Anil Kumar Bajpai,et al.  Responsive polymers in controlled drug delivery , 2008 .

[123]  Denis Wirtz,et al.  Micro- and macrorheology of mucus. , 2009, Advanced drug delivery reviews.

[124]  G. Mullin,et al.  Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease , 1996, Digestive Diseases and Sciences.

[125]  S. Melgar,et al.  Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. , 2011, Drug discovery today.

[126]  B. Tirosh,et al.  Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions. , 1998, Journal of pharmaceutical sciences.

[127]  S. Dai,et al.  Aggregation behavior of methacrylic acid/ethyl acrylate copolymer in dilute solutions , 2000 .

[128]  F. Martin,et al.  Phospholipids and Lipid-Based Formulations in Oral Drug Delivery , 2010, Pharmaceutical Research.

[129]  Didier Merlin,et al.  Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. , 2010, Nature materials.

[130]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.